Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Hisamitsu’s Osteoarthritis Patch Drug Delivers Positive PII Data; PIII Launch Planned in FY2020
November 27, 2019
- Astellas Pharma Grabs China Approval for Xtandi
November 27, 2019
- Kyowa Kirin, Ardelyx Bolster Partnership with Additional Research Deal, US$20 Million Equity Investment
November 27, 2019
- Asahi Kasei to Buy Veloxis for 143.2 Billion Yen, Eyes US Transplant Market
November 26, 2019
- Takeda Set to Pursue 4-Way Global Development, Hails China’s Market Potential
November 26, 2019
- No Need for Acquisitions over Next 5 Years, 12 NMEs to Counter Patent Cliff: Takeda CEO
November 26, 2019
- Takeda’s ALK Drug Yield Positive Update in 1st Line NSCLC
November 26, 2019
- Xofluza Now Available in Taiwan: Shionogi
November 26, 2019
- AnGes to Initiate US Clinical Study for Collategene in Arteriosclerosis Obliterans Patients with Lower Limb Ulcers
November 26, 2019
- Asahi Kasei Pharma Licenses Fasudil to Woolsey; Development of Oral Formulation Expected
November 26, 2019
- Keio Univ. Spin-Off Raises 2.8 Billion Yen to Develop Regenerative Medicine Products for Heart Failure
November 26, 2019
- Mitsubishi Tanabe Kicks Off Multinational PIII of Edaravone Oral Suspension for ALS
November 26, 2019
- Takeda’s Dengue Vaccine Demonstrates Consistent Efficacy in PIII
November 26, 2019
- Sunovion Resubmits Sublingual Parkinson’s Drug in US
November 26, 2019
- AbbVie Enters Japan Oncology Market with Venclexta Rollout
November 25, 2019
- Lung Cancer Drug Portrazza Now Available in Japan: Nippon Kayaku
November 25, 2019
- Takeda R&D Chief Touts Pipeline Revolution, 70% of Research Now in Non-Small Molecules
November 22, 2019
- Parkinson’s Med Haruropi Tape to Hit Shelves on Nov. 29: Kyowa Kirin/Hisamitsu
November 22, 2019
- As BMS Closes Celgene Buy, Japan Integration Gets Underway; 132 Otezla Staffers to Move to Amgen JV
November 22, 2019
- Astellas Links Up with US Health Tech Welldoc in Digital Therapeutics
November 22, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…